With sales of potential blockbuster Lokelma scaling up, AstraZeneca is bolstering its production of the hyperkalemia treatment with a $445 million injection of funds. The investment will increase the capabilities of AZ’s manufacturing facility in Coppell, Texas, which is the company’s lone site in the world that produces Lokelma.
AstraZeneca to spend $445M to boost production of Lokelma at Texas plant
Latest from Blog
How Sea Moss Became a Must-Have Supplement in the Wellness Community
True Sea Moss describes sea moss as a ‘superfood.’ Superfoods have been a major draw for many consumers searching for natural ways to supplement their diets. Post Views: 0
Backed by $32M Mars Investment, Champion Petfoods Opens Next-Gen Pet Nutrition Center
Backed by a $32 million investment from Mars, Champion Pet Foods — a leading global pet food maker and the Alberta-founded maker of ORIJEN and ACANA — is Post Views: 0
Three Nutritional Tools to Help Tackle Heat Stress
Nutrition is playing a bigger role in heat stress management, with yeast, chromium and betaine stepping up as three tools to help ease the impact. Post Views: 0
Every bite counts as we age: How nutrition can help manage and prevent chronic disease
By Dr. Steven Angelo, chief medical officer, UnitedHealthcare Medicare & Retirement of Pennsylvania With warmer months upon us, it’s a natural time to reevaluate our nutrition and fitness routines. There’s […] Post